NCT04895748 2026-03-03
DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies
Novartis
Phase 1 Terminated
Novartis
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Betta Pharmaceuticals Co., Ltd.
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)